Table 1.
Demographic and Clinical Characteristics of the Full Cohort and Stratified by Sex
| Characteristic | Total (N = 460) | Female (n = 211) | Male (n = 249) |
|---|---|---|---|
| ART regimen post-DTG | |||
| ABC/3TC/DTG | 50 (10.9) | 16 (7.6) | 34 (13.7) |
| TDF/3TC/DTG | 410 (89.1) | 195 (92.4) | 215 (86.3) |
| Age at transition to DTG, y | |||
| 10–12 | 135 (29.3) | 56 (26.5) | 79 (31.7) |
| 13–15 | 176 (38.3) | 80 (37.9) | 96 (38.6) |
| 16–19 | 149 (32.4) | 75 (35.5) | 74 (29.7) |
| Median (IQR) | 14.0 (12.0–16.0) | 14.0 (12.0–17.0) | 14.0 (12.0–16.0) |
| Previous ARV regimen | |||
| PI | 4 (0.9) | 2 (0.9) | 2 (0.8) |
| EFV | 111 (24.1) | 58 (27.5) | 53 (21.3) |
| NVP | 345 (75.0) | 151 (71.6) | 194 (77.9) |
| Highest BMI category before DTG | |||
| Thin | 40 (8.7) | 10 (4.7) | 30 (12.0) |
| Normal | 393 (85.4) | 182 (86.3) | 211 (84.7) |
| Overweight/obese | 27 (5.9) | 19 (9.0) | 8 (3.2) |
| Highest BMI category after DTG | |||
| Thin | 33 (7.2) | 10 (4.7) | 23 (9.2) |
| Normal | 396 (86.1) | 177 (83.9) | 219 (88.0) |
| Overweight/obese | 31 (6.7) | 24 (11.4) | 7 (2.8) |
| Mean (SD) BMI before DTG | 18.5 (2.6) | 19.2 (3.0) | 17.8 (2.1) |
| Mean (SD) BMI after DTG | 19.1 (2.7) | 20.1 (3.0) | 18.4 (2.2) |
| Mean (SD) weight before DTG | 41.2 (10.7) | 42.9 (10.3) | 39.7 (10.8) |
| Mean (SD) weight after DTG | 44.4 (10.6) | 46.1 (10.0) | 42.9 (10.9) |
| Mean (SD) height before DTG | 148.0 (12.1) | 148.3 (10.0) | 147.8 (13.6) |
| Mean (SD) height after DTG | 151.2 (11.2) | 150.7 (8.8) | 151.5 (13.0) |
| Mean (SD) CrCl before DTG | 135.6 (28.0) | 134.4 (31.4) | 136.7 (24.8) |
| Mean (SD) CrCl after DTG | 112.2 (21.1) | 109.6 (22.5) | 114.3 (19.7) |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: 3TC, lamivudine; ABC, abacavir; ART, antiretroviral therapy; ARV, antiretroviral; BMI, body mass index; CrCl, creatinine clearance; DTG, dolutegravir; EFV, efavirenz; IQR, interquartile range; NVP, nevirapine; PI, protease inhibitor; SD, standard deviation; TDF, tenofovir disoproxil fumarate.